Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of GANFORT in Chinese Patients with Glaucoma or Ocular Hypertension
NCT02571712Phase 4Completed
- Sponsor
- Allergan
- Start
- Nov 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bimatoprost + timolol in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Allergan. Primary endpoint: Incidence of Adverse Events at 24 weeks. Started Nov 2015; status: completed.
02
Drugs
bimatoprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02571712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571712.